Treatment beyond progression with immune checkpoint inhibitors—known unknowns

JAMA Oncology

Volumn 3, Issue 11, 2017, Pages 1473-1474

  Blumenthal, Gideon M ^a   Theoret, Marc R ^a   Pazdur, Richard ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NIVOLUMAB; IMMUNOLOGIC FACTOR;

CANCER GROWTH; CANCER PATIENT; CANCER THERAPY; EDITORIAL; HUMAN; MELANOMA; NON SMALL CELL LUNG CANCER; RENAL CELL CARCINOMA; TUMOR VOLUME; IMMUNOTHERAPY;

HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; MELANOMA; NIVOLUMAB;

EID: 85037633321     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2017.1819     Document Type: Editorial

References (10)

1. Blumenthal GM, Pazdur R. Approvals in 2016: the march of the checkpoint inhibitors. Nat Rev Clin Oncol. 2017;14(3):131-132.
2. Brawley L. With 20 agents, 803 trials, and 166,736 patient slots, is pharma investing too heavily in PD-1 drug development? The Cancer Letter. 2016;42(37). https://cancerletter.com/articles/20161007_1/. Accessed May 18, 2017.
3. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors (RECIST Guidelines). J Natl Cancer Inst. 2000;92:205-216.
4. Eisenhauer EA, Therasse P, Bogaerts J, et al. New Response Evaluation Criteria in Solid Tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247.
5. Long GV, Weber JS, Larkin J, et al. Nivolumab for patients with advanced melanoma treated beyond progression: analysis of 2 phase 3 clinical trials [published online June 29, 2017]. JAMA Oncol. doi:10.1001/jamaoncol.2017.1588
6. George S, Motzer RJ, Hammers HJ, et al. Safety and efficacy of nivolumab in patients with metastatic renal cell carcinoma treated beyond progression: a subgroup analysis of a randomized clinical trial. JAMA Oncol. 2016;2(9):1179-1186.
7. Escudier B, Motzer RJ, Sharma P, et al. Treatment beyond progression in patients with advanced renal cell carcinoma in the phase III Checkmate 025 study of nivolumab vs everolimus. J Clin Oncol. 2016;34(suppl):abstr 4509.
8. Escudier B, Motzer RJ, Sharma P, et al. Treatment beyond progression in patients with advanced renal cell carcinoma treated with nivolumab in CheckMate 025. Eur Urol. 2017; S0302-2838(17):30265-30268.
9. Kazandjian D, Keegan P, Suzman DL, Pazdur R, Blumenthal GM. Characterization of outcomes in patients with metastatic non-small cell lung cancer treated with programmed cell death protein 1 inhibitors past RECIST version 1.1-defined disease progression in clinical trials. Semin Oncol. 2017;44 (1):3-7.
10. Seymour L, Bogaerts J, Perrone A, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18(3):e143-e152.